Skip to main content
. Author manuscript; available in PMC: 2019 Jun 24.
Published in final edited form as: Eur J Neurosci. 2018 Nov 29;49(1):27–39. doi: 10.1111/ejn.14223

FIGURE 1.

FIGURE 1

CaMKK β activity inhibition by STO-609 induced cell death of human brain microvascular endothelial cells (HBEC-5i) under OGD conditions. (a) Influence of CaMKK β inhibitor STO-609 (1.0–10 μM) on cell viability under normoxic conditions for 24 hr. Cells without STO-609 treatment were considered control cells. MTT reduction assay was used to assess cell viability; (b) and (c) The inhibition of CaMKK β activity with STO-609 under 18-hr OGD with 24 hr of reoxygenation (OGD + Reox) reduced cell viability in HBEC-5i cells in the CCK-8 cell proliferation assay and MTT reduction assay. STO-609 (10 μM) was added prior to OGD and maintained during reoxygenation. Control cells were non-treated cells in normoxic conditions (Norm). Data are expressed as the means ± SEM of at least three independent experiments. *p < 0.05, **p < 0.01 and ***p < 0.001 versus non-treated cells under normoxia. #p < 0.05 between the indicated treatments. Statistical analyses were performed using one-way ANOVA and the Holm-Sidak multiple comparison test